Dec. 2, 2024 — Lunit recently unveiled follow-up findings from the ScreenTrustCAD trial. This study, conducted at Capio S:t Göran Hospital in Sweden, reinforces the real-world impact of Lunit INSIGHT MMG, which has successfully replaced one of the two human readers in the hospital’s double-reading breast cancer screening protocol.
The announcement was made at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago.